Transgenomic, Inc. (TBIO.OB) Announces Acquisition of Clinical Data, Inc.’s Diagnostic Business
Transgenomic, Inc. announced yesterday that they closed the acquisition of Clinical Data, Inc.'s diagnostic business with a sale price of $15.5 million. The Company also has closed on $6.0 million of financing from Third Security, LLC, a leading life sciences investment firm, to fund the cash portion of Transgenomic's acquisition of Clinical Data's diagnostic business. This strategic acquisition provides Transgenomic, Inc. with proprietary genetic commercial tests that have an established revenue base, proprietary biomarker assays, an additional CLIA-certified laboratory operation and established test reimbursement and coverage policies that offer access to testing for an estimated 280 million patients. Commenting on…